Wei Xixi, Wang Yang, Zhao Wanlong, Yang Wenqian, Tang Jiaping, Zhao Baosheng, Liu Yuzhen
Henan Key Laboratory of Neurorestoratology, Life Science Research Center, The First Affiliated Hospital of Henan Medical University, Weihui, Henan 453100, P.R. China.
Department of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Henan 453100, P.R. China.
Int J Oncol. 2025 Sep;67(3). doi: 10.3892/ijo.2025.5779. Epub 2025 Aug 1.
Glioma is a common and aggressive malignant brain tumor. Despite advances in research, the mechanisms driving glioma initiation and progression remain incompletely understood. The present study aimed to assess the role of acetyl‑CoA carboxylase 1 (ACC1) in glioma, focusing on its mechanistic function in U251 cells and its clinical significance. ACC1 expression was first assessed in four glioma cell lines and then the effects on cellular functions were evaluated. Based on the finding that ACC1 knockdown altered the phenotype of U251 cells, potentially through modulation of succinate dehydrogenase (SDH) activity, further mechanistic assessments were performed. Finally, the association between ACC1 expression and patient prognosis was analyzed. The results demonstrated that ACC1 overexpression inhibited proliferation, migration and invasion in U87 cells. Conversely, ACC1 knockdown promoted these processes in U251, T98G and LN229 cells. Mechanistically, in U251 cells, ACC1 knockdown increased acetyl‑CoA levels, enhancing substrate availability for P300. This led to upregulation of DNA methyltransferase 1 (DNMT1), hypermethylation of the SDH promoter and subsequent SDH downregulation. The resulting increase in reactive oxygen species (ROS) levels promoted U251 cell migration and invasion. Analysis of clinical data revealed a significant correlation between low ACC1 expression and poor survival outcomes in patients with glioma. These findings suggest that ACC1 functions as a tumor suppressor in glioma. Its downregulation promotes a pro‑tumorigenic phenotype via the acetyl‑CoA/P300/DNMT1/SDH/ROS pathway, highlighting its potential as a prognostic marker and therapeutic target. This underscores the importance of developing personalized treatment strategies targeting ACC1 in glioma.
胶质瘤是一种常见的侵袭性恶性脑肿瘤。尽管研究取得了进展,但驱动胶质瘤起始和进展的机制仍未完全阐明。本研究旨在评估乙酰辅酶A羧化酶1(ACC1)在胶质瘤中的作用,重点关注其在U251细胞中的机制功能及其临床意义。首先在四种胶质瘤细胞系中评估ACC1表达,然后评估其对细胞功能的影响。基于ACC1敲低改变U251细胞表型这一发现,可能是通过调节琥珀酸脱氢酶(SDH)活性,进行了进一步的机制评估。最后,分析了ACC1表达与患者预后之间的关联。结果表明,ACC1过表达抑制U87细胞的增殖、迁移和侵袭。相反,ACC1敲低促进U251、T98G和LN229细胞中的这些过程。机制上,在U251细胞中,ACC1敲低增加了乙酰辅酶A水平,提高了P300的底物可用性。这导致DNA甲基转移酶1(DNMT1)上调、SDH启动子高甲基化以及随后的SDH下调。活性氧(ROS)水平的升高促进了U251细胞的迁移和侵袭。临床数据分析显示,胶质瘤患者中低ACC1表达与不良生存结果之间存在显著相关性。这些发现表明,ACC1在胶质瘤中作为肿瘤抑制因子发挥作用。其下调通过乙酰辅酶A/P300/DNMT1/SDH/ROS途径促进促肿瘤表型,突出了其作为预后标志物和治疗靶点的潜力。这强调了开发针对胶质瘤中ACC1的个性化治疗策略的重要性。